However, he thinks that biosimilars will “not significantly” change the landscape of health economics.
Asked whether the costs alone should drive such an analysis, since biosimilars are based on therapies with prior approval, Dr. Severens said the evidence on biosimilars is not yet conclusive enough to allow that.
ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE
“Only when we are very, very sure about short-term outcome and long-term outcome can we stick to what we call cost-minimization analysis,” or strictly focusing on costs, he said.
Thomas R. Collins is a freelance medical writer based in Florida.
ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE